Item 5.07 Submission of Matters to a Vote of Security Holders
On October 22, 2021, TCR2 Therapeutics Inc. (the "Company") held its Annual
Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the
Company's stockholders considered and voted on the two proposals set forth
below, each of which is described in greater detail in the Company's Proxy
Statement filed with the Securities and Exchange Commission on September 3,
2021. The final voting results are set forth below.
Proposal 1 - Election of Class III Director Nominees
The stockholders of the Company elected Garry E. Menzel, Ph.D., Ansbert Gadicke,
M.D., and Neil Gibson, Ph.D., as a Class III directors, for a three-year term
ending at the annual meeting of stockholders to be held in 2024 and until each
director's successor has been duly elected and qualified or until his earlier
resignation or removal. The results of the stockholders' vote with respect to
the election of the Class III directors were as follows:
Votes Votes Broker
Name For Withheld Non-Votes
Garry E. Menzel, Ph.D. 23,062,461.41 3,651,095 3,803,285
Ansbert Gadicke, M.D. 23,230,375.41 3,483,181 3,803,285
Neil Gibson, Ph.D. 23,282,444.41 3,431,112 3,803,285
Proposal 2 - Ratification of Appointment of Independent Registered Public
Accounting Firm
The stockholders of the Company ratified the selection of KPMG LLP as the
Company's independent registered public accounting firm for the fiscal year
ending December 31, 2021. The results of the stockholders' vote with respect to
such ratification were as follows:
Votes Votes Broker
For Against Abstain Non-Votes
30,489,743.41 21,712 5,386 0
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses